



DEEP DIAMOND INDIA LIMITED

Regd. Office: 408, Corporate Avenue, Sonawala Road, Near Udyog Bhavan,
Goregaon (East), Mumbai, Maharashtra 400063 CIN: L24100MH1994PLC082609
[Tel:022-46065770](tel:022-46065770)

E-mail: info.deepdiamondltd@gmail.com Website: www.deepdiamondltd.co.in

Date: July 13, 2023

To,

BSE Limited

Address: Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400001

Script Code: 539559

Subject: Disclosure pursuant to Regulation 30 Part A of Schedule III of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) - Acquisition of M/s Microcure Biotech Private Limited.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Clause 1 of Para A of Part A of Schedule III of Listing Regulations, please note that based on the Scrutinizer's Report dated July 12, 2023, the shareholders of the Company through Postal Ballot (through remote e-voting), inter-alia, have approved the acquisition of M/s Microcure Biotech Private Limited bearing CIN: U24100RJ2021PTC073022 by Ordinary Resolution.

Disclosure required under SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 is given in the enclosed Annexure-1.

This intimation is also available on the website i.e., www.deepdiamondltd.co.in

Kindly take the same on records.

Thanking you.

For Deep Diamond India Limited

Ganpat Lal Nyati
Managing Director
DIN: 09608005

Date: July 13, 2023

Place: Mumbai



DEEP DIAMOND INDIA LIMITED

Regd. Office: 408, Corporate Avenue, Sonawala Road, Near Udyog Bhavan,
Goregaon (East), Mumbai, Maharashtra 400063 CIN: L24100MH1994PLC082609
[Tel:022-46065770](tel:022-46065770)

E-mail: info.deepdiamondltd@gmail.com Website: www.deepdiamondltd.co.in

Annexure 1

Sr. No	Particulars	Details
1	Name of the target entity details in brief such as size, turnover etc.	Name: M/s Microcure Biotech Private Limited Authorized Share capital: Rs.2,00,000/- Size/Turnover: NIL
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?	Yes, the Target Company would fall within related party transaction(s) as Mr. Narendra Kumar Shrimali Director of the Company is also the Director in M/s Microcure Biotech Private Limited
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and effects of acquisition	Object: Considering the future plans of the Company Effect: Business of the Company is in line with the main objects of the Company
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	On or before the July 30, 2023
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash consideration
8	Cost of acquisition or the price at which the shares are acquired	Restricted to Rs. 1,83,400
9	Percentage of shareholding:	100% of paid- u p share capital of the Company.
10	Line of business acquired Date of incorporation	The Company is in the business of manufacturing basic Pharma & FMCG products. January 19, 2021